Diagnosis and risk stratification in patients with anti-RNP autoimmunity

Introduction Anti-RNP autoantibodies occur either in mixed connective tissue disease (MCTD) (with a frequently favorable prognosis), or in systemic lupus erythematosus (SLE) cases with aggressive major organ disease. It is uncertain how to assess for the risk of severe disease in anti-RNP + patients...

Full description

Saved in:
Bibliographic Details
Published in:Lupus 2015-09, Vol.24 (10), p.1057-1066
Main Authors: Carpintero, M F, Martinez, L, Fernandez, I, Romero, A C Garza, Mejia, C, Zang, Y J, Hoffman, R W, Greidinger, E L
Format: Article
Language:English
Subjects:
Adult
Antibodies
Antibodies, Antinuclear - immunology
Antigens
Autoantibodies - blood
Autoantibodies - metabolism
Biomarkers - blood
Case-Control Studies
Cohort Studies
Connective tissue diseases
Female
Gene Expression
Humans
Interferon
Kidney diseases
Lung diseases
Lupus
Lupus Erythematosus, Systemic - blood
Lupus Erythematosus, Systemic - diagnosis
Lupus Erythematosus, Systemic - immunology
Male
Medical laboratories
Middle Aged
Mixed Connective Tissue Disease - blood
Mixed Connective Tissue Disease - diagnosis
Mixed Connective Tissue Disease - immunology
Pulmonary hypertension
Raynaud disease
Raynaud Disease - immunology
Review boards
Rheumatology
Ribonucleoproteins - antagonists & inhibitors
Ribonucleoproteins - immunology
Risk Assessment - methods
RNA - blood
RNA - genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Anti-RNP autoantibodies occur either in mixed connective tissue disease (MCTD) (with a frequently favorable prognosis), or in systemic lupus erythematosus (SLE) cases with aggressive major organ disease. It is uncertain how to assess for the risk of severe disease in anti-RNP + patients. Methods Following institutional review board-approved protocols, clinical data and blood were collected from patients with known or suspected anti-RNP autoimmunity and normal controls in a cohort study. Samples were screened for parameters of immune activation. Groups were compared based on clinical diagnoses, disease classification criteria, disease activity and specific end-organ clinical manifestations. Results Ninety-seven per cent of patients satisfying Alarcon-Segovia MCTD criteria also met Systemic Lupus International Collaborating Clinic (SLICC) SLE criteria, while 47% of the anti-RNP + SLE patients also met MCTD criteria. Among SLICC SLE patients, MCTD criteria were associated with reduced rates of renal disease (odds ratio (OR) 4.3, 95% confidence interval (CI) 1.3–14.0), increased rates of Raynaud's phenomenon (OR 3.5, 95% CI 1.3–9.5) and increased serum B-cell maturation antigen, transmembrane activator and CAML interactor and TNFα levels. Circulating immune markers and markers of type I interferon activation were not effective at distinguishing clinical subgroups. Conclusions Among anti-RNP patients, the question of MCTD versus SLE is not either/or: most MCTD patients also have lupus. MCTD classification criteria (but not a broad set of immune markers) distinguish a subset of SLE patients at reduced risk for renal disease.
ISSN:0961-2033
1477-0962
DOI:10.1177/0961203315575586